Radiopharmaceutical Drug based on Aluminum Oxide

Background/Objectives: The regularities of adsorption 99mТс on activated nanoscale powder gamma-oxide Al2O3 were investigated. Methods/Statistical Analysis: As object of examination nanopowder low-temperature (cubic) modification of gamma-oxide Al2O3 is used. The area of specific surface of aluminum oxide was 320 m2/g. According to submicroscopy, the particles had the improper shape and a rough surface. For obtaining of an initial drug 99mTc (eluate) in the form of a sodium pertechnetate solution, 99mTc was produced with the chromatographic generator of “99mTc-GT-TOM” productions of PTI TPU. The stability of the complex was determined by measuring the RCP at room temperature (24°C) at different time points (0, 1, 2, 4 h) after preparation. Findings: It is shown that sorption capacity of aluminum oxide essentially depends on its acid treatment. Experimental research of process of adsorption 99mTc in the presence of reducing agent of tin (II) is made. It’s necessary and sufficient amount providing full “reducibleness” 99mТс in a reaction mixture is spotted. For yield rising nanocolloids with particle size less than 100 nanometers and risings of radiochemical purity of drugs additives of sodium pyrophosphate, ascorbic acid and gelatine were used. Pre-award medicobiological tests of nanocolloids preparate 99mTs-Al2O3 on the observational animals to define the functional operability for scintigraphic visualisation of lymph nodes are conducted. Applications/Improvements: Is of practical importance for carrying out of diagnostic researches in cardiology, oncology and other fields of medicine.